These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8376683)

  • 1. Efficacy of vasodilators in the treatment of heart failure.
    Cohn JN
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):135A-138A. PubMed ID: 8376683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of vasodilators in the treatment of congestive heart failure.
    Levine TB
    Am J Cardiol; 1985 Jan; 55(2):32A-35A. PubMed ID: 2981463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can we expect vasodilator therapy to prolong life in patients with congestive heart failure?
    Packer M; Lee WH; Kessler PD; Gottlieb SS
    J Cardiovasc Pharmacol; 1987; 9 Suppl 2():S73-5. PubMed ID: 2441205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
    Cohn JN; Archibald DG; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Francis GS; Flohr KH
    N Engl J Med; 1986 Jun; 314(24):1547-52. PubMed ID: 3520315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of infarct related heart failure: vasodilators other than ACE inhibitors.
    Cohn JN
    Cardiovasc Drugs Ther; 1994 Feb; 8(1):119-22. PubMed ID: 8086321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of vasodilators and long-term response in heart failure.
    Franciosa JA; Dunkman WB; Leddy CL
    J Am Coll Cardiol; 1984 Jun; 3(6):1521-30. PubMed ID: 6325522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
    Chow MS
    Pharmacotherapy; 1993; 13(5 Pt 2):82S-87S. PubMed ID: 8233997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure.
    Packer M
    Eur Heart J; 1988 Jun; 9 Suppl H():105-8. PubMed ID: 2901957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.
    Cohn JN
    Drugs; 1994; 47 Suppl 4():47-57; discussion 57-8. PubMed ID: 7523062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R; Kunstmann S; Jalil J
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of vasodilator therapy in the treatment of severe chronic heart failure.
    Packer M
    Drugs; 1986; 32 Suppl 5():13-26. PubMed ID: 3552590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of vasodilator therapy in congestive heart failure. Effects on mortality.
    Greenberg B
    Cardiol Clin; 1994 Feb; 12(1):87-99. PubMed ID: 8181028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasodilator therapy for congestive heart failure. Lessons from mortality trials.
    Groden DL
    Arch Intern Med; 1993 Feb; 153(4):445-54. PubMed ID: 8435024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors.
    Gottlieb SS; Kukin ML; Penn J; Fisher ML; Cines M; Medina N; Yushak M; Taylor M; Packer M
    J Am Coll Cardiol; 1993 Oct; 22(4):963-7. PubMed ID: 8409070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and long-term effects of vasodilator therapy on resting and exercise hemodynamics and exercise tolerance.
    Massie BM; Kramer B; Haughom F
    Circulation; 1981 Dec; 64(6):1218-26. PubMed ID: 6794935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vasodilator agents: the lesson from large clinical trials].
    Galiè N; Magelli C; Rapezzi C; Branzi A; Magnani B
    Cardiologia; 1993 Dec; 38(12 Suppl 1):221-6. PubMed ID: 8020020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
    Thadani U; Jacob RG
    Drugs Today (Barc); 2008 Dec; 44(12):925-37. PubMed ID: 19198701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vasodilator therapy in cardiac failure].
    Akatsuka N
    Nihon Rinsho; 1993 May; 51(5):1276-80. PubMed ID: 8101237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.